CN1982471B - 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 - Google Patents
多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 Download PDFInfo
- Publication number
- CN1982471B CN1982471B CN2005101305281A CN200510130528A CN1982471B CN 1982471 B CN1982471 B CN 1982471B CN 2005101305281 A CN2005101305281 A CN 2005101305281A CN 200510130528 A CN200510130528 A CN 200510130528A CN 1982471 B CN1982471 B CN 1982471B
- Authority
- CN
- China
- Prior art keywords
- genotype
- pleomorphism site
- mthfr
- homozygous
- action effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 97
- 238000000034 method Methods 0.000 title abstract description 59
- 239000002532 enzyme inhibitor Substances 0.000 title description 5
- 229940125532 enzyme inhibitor Drugs 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 320
- 230000037353 metabolic pathway Effects 0.000 claims abstract description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims description 298
- 230000009471 action Effects 0.000 claims description 206
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 184
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 165
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 163
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 145
- 239000008194 pharmaceutical composition Substances 0.000 claims description 137
- 206010020772 Hypertension Diseases 0.000 claims description 81
- 108010061435 Enalapril Proteins 0.000 claims description 78
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 78
- 239000011724 folic acid Substances 0.000 claims description 75
- 235000019152 folic acid Nutrition 0.000 claims description 75
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 69
- 229960000304 folic acid Drugs 0.000 claims description 69
- 229960000873 enalapril Drugs 0.000 claims description 51
- 230000000630 rising effect Effects 0.000 claims description 49
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 40
- 229960004530 benazepril Drugs 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 37
- 108010007859 Lisinopril Proteins 0.000 claims description 36
- 229960002394 lisinopril Drugs 0.000 claims description 36
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 36
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 229960002490 fosinopril Drugs 0.000 claims description 33
- 101150044508 key gene Proteins 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 230000002441 reversible effect Effects 0.000 claims description 12
- 108700028369 Alleles Proteins 0.000 claims description 10
- 230000003907 kidney function Effects 0.000 claims description 9
- 229960000830 captopril Drugs 0.000 claims description 8
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 8
- 229960005227 delapril Drugs 0.000 claims description 8
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 8
- 229960001195 imidapril Drugs 0.000 claims description 8
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 8
- 229960002582 perindopril Drugs 0.000 claims description 8
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 8
- 229960001455 quinapril Drugs 0.000 claims description 8
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 8
- 229960003401 ramipril Drugs 0.000 claims description 8
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 229960002769 zofenopril Drugs 0.000 claims description 8
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000002751 oligonucleotide probe Substances 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000003028 elevating effect Effects 0.000 claims description 3
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 9
- 235000018417 cysteine Nutrition 0.000 abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000005541 ACE inhibitor Substances 0.000 description 229
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 229
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 229
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 229
- 230000035772 mutation Effects 0.000 description 90
- 229930003270 Vitamin B Natural products 0.000 description 84
- 235000019156 vitamin B Nutrition 0.000 description 84
- 239000011720 vitamin B Substances 0.000 description 84
- 102100024614 Methionine synthase reductase Human genes 0.000 description 67
- 208000019423 liver disease Diseases 0.000 description 67
- 101001116314 Homo sapiens Methionine synthase reductase Proteins 0.000 description 66
- 238000003752 polymerase chain reaction Methods 0.000 description 45
- 238000011282 treatment Methods 0.000 description 35
- 230000001631 hypertensive effect Effects 0.000 description 34
- 229960002680 enalaprilat Drugs 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- 230000036772 blood pressure Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 24
- 230000000391 smoking effect Effects 0.000 description 24
- 230000000857 drug effect Effects 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000035487 diastolic blood pressure Effects 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 101150082137 Mtrr gene Proteins 0.000 description 14
- 230000003908 liver function Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 102200088705 rs1801394 Human genes 0.000 description 13
- 230000035488 systolic blood pressure Effects 0.000 description 13
- 230000003276 anti-hypertensive effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 229930003779 Vitamin B12 Natural products 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 10
- 235000019163 vitamin B12 Nutrition 0.000 description 10
- 239000011715 vitamin B12 Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000001077 hypotensive effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 238000010306 acid treatment Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102200088757 rs10380 Human genes 0.000 description 7
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 6
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 239000002220 antihypertensive agent Substances 0.000 description 6
- 229940127088 antihypertensive drug Drugs 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 206010042957 Systolic hypertension Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 102220342871 rs1555751995 Human genes 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 4
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108050000824 Angiotensin II receptor Proteins 0.000 description 4
- 102000008873 Angiotensin II receptor Human genes 0.000 description 4
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102200088972 rs1801133 Human genes 0.000 description 4
- 102220099072 rs370493415 Human genes 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 206010062237 Renal impairment Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 231100000857 poor renal function Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000003340 retarding agent Substances 0.000 description 3
- 102200044221 rs10138997 Human genes 0.000 description 3
- 102200011860 rs111033800 Human genes 0.000 description 3
- 102220149202 rs142221815 Human genes 0.000 description 3
- 102200088712 rs162036 Human genes 0.000 description 3
- 102200088760 rs16879334 Human genes 0.000 description 3
- 102200088762 rs16879355 Human genes 0.000 description 3
- 102200088696 rs2287780 Human genes 0.000 description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010066671 Enalaprilat Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101100514680 Homo sapiens MTHFR gene Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- 206010051078 Lacunar infarction Diseases 0.000 description 2
- 108030006431 Methionine synthases Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010042865 aquacobalamin reductase Proteins 0.000 description 2
- 101150036080 at gene Proteins 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220393080 c.1015C>T Human genes 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical class [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940064302 folacin Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 2
- 235000007672 methylcobalamin Nutrition 0.000 description 2
- 239000011585 methylcobalamin Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001915 proofreading effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 102220027851 rs267607934 Human genes 0.000 description 2
- 102220084342 rs863224900 Human genes 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 101150100998 Ace gene Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 101150019913 MTHFR gene Proteins 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000028284 monogenic inheritance Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102200088679 rs1801131 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101305281A CN1982471B (zh) | 2005-12-14 | 2005-12-14 | 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 |
US11/638,634 US20070134709A1 (en) | 2005-12-14 | 2006-12-13 | Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101305281A CN1982471B (zh) | 2005-12-14 | 2005-12-14 | 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1982471A CN1982471A (zh) | 2007-06-20 |
CN1982471B true CN1982471B (zh) | 2011-12-14 |
Family
ID=38165312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101305281A Active CN1982471B (zh) | 2005-12-14 | 2005-12-14 | 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1982471B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616259A (zh) * | 2019-09-02 | 2019-12-27 | 珠海赛乐奇生物技术股份有限公司 | 用于检测叶酸基因多态性的探针、基因芯片及试剂盒 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396561A (zh) * | 2007-09-28 | 2009-04-01 | 北京华安佛医药研究中心有限公司 | 含有acei的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途 |
CN103374608B (zh) * | 2012-04-12 | 2014-11-26 | 益善生物技术股份有限公司 | Mtrr基因突变检测特异性引物和液相芯片 |
CN106874710A (zh) * | 2016-12-29 | 2017-06-20 | 安诺优达基因科技(北京)有限公司 | 一种用于利用肿瘤ffpe样本检测体细胞突变的装置 |
CN107245527A (zh) * | 2017-07-25 | 2017-10-13 | 重庆京因生物科技有限责任公司 | Mtrr基因多态性快速检测的引物、分子信标、试剂盒及其检测方法 |
CN109852683A (zh) * | 2018-12-30 | 2019-06-07 | 济南齐鲁医学检验有限公司 | rs1801133基因型高效分型检测试剂盒 |
-
2005
- 2005-12-14 CN CN2005101305281A patent/CN1982471B/zh active Active
Non-Patent Citations (5)
Title |
---|
Jiang S et al.A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study.《Clin Exp Hypertens》.2005,第27卷(第6期),第509-521页. * |
Phillip A et al.Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms:An examination of C677T and A1298C mutations.《Am.J.Hum.Genet》.2000,第67卷第986-990页. * |
Prevention》.2002,第11卷第1161-1621页. * |
Temitope Keku et al.5,10-Methylenetetrahydrofolate Reductase Codon 677 and 1298 Polymorphisms and Colon Cancer in African Americans and Whites1.《Cancer Epidemiology, Biomarkers & Prevention》.2002,第11卷第1161-1621页. |
Temitope Keku et al.5,10-Methylenetetrahydrofolate Reductase Codon 677 and 1298 Polymorphisms and Colon Cancer in African Americans and Whites1.《Cancer Epidemiology, Biomarkers & * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616259A (zh) * | 2019-09-02 | 2019-12-27 | 珠海赛乐奇生物技术股份有限公司 | 用于检测叶酸基因多态性的探针、基因芯片及试剂盒 |
WO2021042884A1 (zh) * | 2019-09-02 | 2021-03-11 | 珠海赛乐奇生物技术股份有限公司 | 用于检测叶酸基因多态性的探针、基因芯片及试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN1982471A (zh) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070134709A1 (en) | Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit | |
Hingorani et al. | Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition | |
US7179597B2 (en) | Genetic diagnosis for QT prolongation related adverse drug reactions | |
Ashavaid et al. | ACE and AT1R gene polymorphisms and hypertension in Indian population | |
CN1982471B (zh) | 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 | |
Kikuchi et al. | Early and late postmenopausal bone loss is associated with BsmI vitamin D receptor gene polymorphism in Japanese women | |
Sun et al. | Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial | |
CN101096705A (zh) | 多态性位点基因型预测心脑血管疾病发生及预后的用途、方法和试剂盒 | |
Martinez et al. | Angiotensin-converting enzyme (ACE) gene polymorphisms, serum ACE activity and blood pressure in a Spanish-Mediterranean population | |
JP2001519660A (ja) | 心臓血管の状態を評価するための方法およびそれを用いるための組成物 | |
CN101008032A (zh) | 多态性位点基因型预测磺脲类药物作用效果的用途和方法 | |
Jenkins et al. | Preeclampsia risk and angiotensinogen polymorphisms M235T and AGT-217 in African American and Caucasian women | |
CN1858240B (zh) | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 | |
WO2010102387A1 (en) | Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis | |
WO2007067263A2 (en) | Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders | |
CN101037708B (zh) | 多态性位点基因型预测同型半胱氨酸水平的用途、方法和试剂盒 | |
Antoniades et al. | Genetic polymorphisms G894T on the eNOS gene is associated with endothelial function and vWF levels in premature myocardial infarction survivors | |
Szolnoki et al. | Lymphotoxin-α gene 252G allelic variant is a risk factor for large-vessel-associated ischemic stroke | |
US20090018110A1 (en) | Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH) | |
CN101063166B (zh) | 预测血管紧张素转换酶抑制剂类药物作用效果的试剂盒 | |
US20030165928A1 (en) | Susceptibility to bone damage | |
CN107447035A (zh) | 华法林药物遗传学基因cyp2c9和vkorc1多态性检测试剂盒 | |
Hubacek et al. | Variable expression of hypercholesterolemia in apolipoprotein E2^*(Arg136→ Cys) heterozygotes | |
Lee et al. | Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients | |
CN1827776B (zh) | 一种预测钙拮抗剂药物药效的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ANHUI RESEARCH INSTITUTE OF BIOMEDICINE Effective date: 20121207 Owner name: ANHUI HUA'ANFO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUA'ANFO MEDICINE RESEARCH CENTER CO., LTD., BEIJING Effective date: 20121207 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100026 CHAOYANG, BEIJING TO: 230032 HEFEI, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121207 Address after: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Patentee after: Huaan Anhui Buddha Pharmaceutical Co., Ltd. Address before: 100026 Beijing city Chaoyang District tianshuiyuan Street No. 6 Patentee before: Hua'anfo Medicine Research Center Co., Ltd., Beijing Patentee before: Anhui Biological Medical Science Inst. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Use, method and kit of polymorphism locus gene type predict agiotensin converter enzyme inhibitor Effective date of registration: 20130523 Granted publication date: 20111214 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Huaan Anhui Buddha Pharmaceutical Co., Ltd. Registration number: 2013990000311 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20111214 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Huaan Anhui Buddha Pharmaceutical Co., Ltd. Registration number: 2013990000311 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000311 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160818 Address after: 518057, Nanshan District hi tech Zone, Shenzhen, a high-tech incubator in No. 16, three, 2, building first, second, building 3, 1, East and 2, 3, and Guangdong Patentee after: Shenzhen Aosa Pharmaceutical Co., Ltd. Address before: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Patentee before: Huaan Anhui Buddha Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210107 Address after: 518057 Guangdong Province Nanshan District Yuehai Street, Shenzhen City, Guangdong Province, 16 Biological Incubator Phase III Building on the east side of the second floor and the east side of the fourth floor and the fourth floor of the second floor and the fourth floor of the second floor Patentee after: SHENZHEN TAILEDE MEDICAL Co.,Ltd. Address before: 518057 the 1st and 2nd floors of Building 2, phase III of biological incubator, No.16, Gaoxin Zhongyi Road, central high tech Zone, Nanshan District, Shenzhen City, Guangdong Province; the east side of the 1st floor and the 2nd and 3rd floors of building 3 Patentee before: AUSA PHARMED Ltd. |